By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Agios Pharmaceuticals 

38 Sidney Street
2nd Floor
Cambridge  Massachusetts  02139-4169  U.S.A.
Phone: 617-649-8600 Fax: n/a


SEARCH JOBS

Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic metabolic disorders through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.

YEAR FOUNDED:

August 7, 2007

LEADERSHIP:

Founders: Lewis Cantley, Tak Mak, Craig Thompson, Shin-San Michael Su

CEO: David Schenkein

CMO (Medical): Chris Bowden

CSO (Scientific): Scott Biller

JOBS:

Please click here for Agios job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.


Key Statistics


Email:
Ownership: Public

Web Site: Agios
Employees:
Symbol: AGIO
 









Company News
Agios (AGIO) Presents Phase I Data From Dose-Escalation And Expansion Cohorts Of AG-120 (Ivosidenib) In Patients With IDH1 Mutant Positive Cholangiocarcinoma 6/6/2017 3:08:08 PM
Agios (AGIO) Appoints David Scadden, M.D., To The Board Of Directors 6/1/2017 12:37:35 PM
Agios (AGIO) To Present New Clinical Data From Its IDH Programs At ASCO 5/18/2017 10:55:47 AM
Thermo Fisher Scientific (TMO) Signs Development Agreement With Agios (AGIO) For Next-Generation Sequencing Oncology Companion Diagnostic In Cholangiocarcinoma 5/18/2017 6:43:44 AM
Agios (AGIO) Reports First Quarter 2017 Financial Results 5/4/2017 11:21:14 AM
Agios (AGIO) Announces Closing Of Over-Allotment Option In Public Offering 5/1/2017 12:07:05 PM
Agios (AGIO) And Aurigene Discovery Technologies Limited Enter Into Exclusive License Agreement For Novel Small Molecules For Cancer Metabolism Target 4/27/2017 11:12:43 AM
Agios (AGIO) Announces Exercise Of Over-Allotment Option In Public Offering 4/26/2017 10:33:13 AM
Agios (AGIO) Announces Closing Of Public Offering 4/25/2017 10:01:01 AM
Agios (AGIO) Announces Pricing Of $250 Million Public Offering Of Common Stock 4/19/2017 8:54:56 AM
12345678910...
//-->